产品名称
美沙拉嗪, European Pharmacopoeia (EP) Reference Standard
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
SMILES string
Nc1ccc(O)c(c1)C(O)=O
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
mesalazine, mesalamine
manufacturer/tradename
EDQM
mp
275-280 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Gene Information
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
No data available
flash_point_c
No data available
Marietta Iacucci et al.
Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 24(2), 127-133 (2010-02-13)
5-aminosalicylic acid (5-ASA) preparations (eg, mesalazine, mesalamine) are well-established preparations used in the management of inflammatory bowel disease. These drugs are most useful for the treatment of mild to moderate flares of ulcerative colitis and, especially, for maintenance of remission.
A H Steinhart et al.
Alimentary pharmacology & therapeutics, 25(12), 1389-1399 (2007-06-02)
To evaluate the effectiveness of pH 6-/pH 7-dependent and controlled-release mesalazines in maintaining medically and surgically induced Crohn's disease remission. A systematic search identified 13 randomized controlled trials (RCTs). The rate of symptomatic relapse (Crohn's disease activity index >150, or
Altamash I Qureshi et al.
Advanced drug delivery reviews, 57(2), 281-302 (2004-11-24)
Sulfasalazine's role as the first-line of therapy in patients with inflammatory bowel disease has led to the development of other "designer" aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel. Olsalazine sodium
P D R Higgins et al.
Alimentary pharmacology & therapeutics, 29(3), 247-257 (2008-10-24)
Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis. To perform a systematic review of the published literature
A M Schoepfer et al.
Alimentary pharmacology & therapeutics, 40(8), 930-937 (2014-08-26)
There is uncertain evidence of effectiveness of 5-aminosalicylates (5-ASA) to induce and maintain response and remission of active Crohn's disease (CD), and weak evidence to support their use in post-operative CD. To assess the frequency and determinants of 5-ASA use
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持